Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. More Info... ×
  • Welcome to Celiac.com!

    You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.




  • Celiac.com Sponsor (A1):



    Celiac.com Sponsor (A1-M):


  • Get Celiac.com Updates:
    Where Your Contribution Counts!
    eNewsletter
    Support Us!
  • Jefferson Adams
    Jefferson Adams

    Escalating Doses of Nexvax2 Avoids Adverse Symptoms, Raises Patient Tolerance

    Reviewed and edited by a celiac disease expert.
    Escalating Doses of Nexvax2 Avoids Adverse Symptoms, Raises Patient Tolerance - Image: CC--NIAID
    Caption: Image: CC--NIAID

    Celiac.com 01/04/2018 - Nexvax2 is a peptide-based, epitope-specific immunotherapy intended to reduce reactions to natural gluten exposure, and ultimately restore tolerance to gluten in patients with celiac disease.

    Celiac disease patients who received fixed intradermal doses of Nexvax2 lost their sensitivity to the HLA-DQ2·5-restricted gluten epitopes in Nexvax2, but their tolerance was limited to 150 μg, due to gastrointestinal symptoms and cytokine release, mimicking gluten exposure, that accompany the first dose.

    Celiac.com Sponsor (A12):
    A team of researchers recently set out to test whether small doses in steps might reduce the first dose effect of Nexvax2 in celiac disease patients.

    The research team included James M. Daveson, Hooi C. E, Jane M. Andrews, Timothy King, Kaela E. Goldstein, John L. Dzuris, James A. MacDougall; Leslie J. Williams, Anita Treohan, Michael P. Cooreman, and Robert P. Anderson.

    They are variously associated with the Faculty of Medicine, University of Queensland, QLD, Australia b Department of Gastroenterology, Sir Charles Gairdner Hospital, WA, Australia; Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, SA, Australia; Department of Gastroenterology, Auckland City Hospital, Auckland, New Zealand; PROMETRIKA, LLC, Cambridge, MA, USA; and ImmusanT Inc., Cambridge, MA, USA.

    The team conducted a randomized, double-blind, placebo-controlled trial at four community sites in Australia (3) and New Zealand (1) in HLA-DQ2·5 genotype positive adults with celiac disease who were on a gluten-free diet.

    By using doses escalated from 3 μg up to 300 μg in HLA-DQ2·5 homozygotes or to 900 μg in HLADQ2.5 non-homozygotes the team was able to eliminate the adverse events and cytokine release that had limited the previous maximum dose to 150 μg.

    Administration of Nexvax2 at dose levels from 150 μg to 900 μg preceded by dose escalation was not associated with elevations in plasma cytokines at 4 h.

    Otherwise, the most common treatment-related side effects in the Nexvax2 participants were headache (52%), diarrhea (48%), nausea (37%), abdominal pain (26%), and abdominal discomfort (19%).

    This study shows that antigenic peptides recognized by CD4-positive T cells in an autoimmune disease can be safely administered to patients at high maintenance dose levels without immune activation when preceded by gradual dose escalation.

    These findings help further these efforts to develop a successful immunotherapy drug to treat celiac disease.

    Read more at Ebiomedicine.com

    This completed trial is registered with ClinicalTrials. gov, number NCT02528799.

     



    User Feedback

    Recommended Comments

    Guest Laura

    Defense cells use "cytokines" to communicate with one another or with other body cells. They are needed as a defense against infected or cancerous cells. Cytokines are released by many cells of the immune system. Cytokines stimulate the growth and maturity of cells. This form of immunotherapy might prevent triggering a gluten response. Ask yourself; Is it worth the risk of developing a raging infection or cancer in order to once again consume wheat products? Wheat contains gluten and gliadin that are known to be the underlying cause of many inflammatory and endocrinological diseases. Is it worth the risk? Judge for yourself; Are these immunologists concerned more with cashing in on the almighty pharmaceutical drug dollars or you?

    Link to comment
    Share on other sites
    Guest coloradosue

    Posted

    I watched my younger spend the last 14 years of her life dying from lymphoma from undignosed celiac disease. I was diagnosed in 2004 with celiac disease. I just had another ER visit from ingesting gluten. This theraphy sounds promising but not enough to try it. I will continue being gluten free. Besides, there have been so much advancement in quality of gluten free products in just the past 10 years that I can't see changing back over to wheat products. Enough said!

    Link to comment
    Share on other sites
    HannahBick

    I would be very surprised if someone with celiac disease could eat gluten after a series of these shots. 

    Link to comment
    Share on other sites


    Create an account or sign in to comment

    You need to be a member in order to leave a comment

    Create an account

    Sign up for a new account in our community. It's easy!

    Register a new account

    Sign in

    Already have an account? Sign in here.

    Sign In Now

  • Get Celiac.com Updates:
    Help Celiac.com:
    Donate
  • About Me

    Jefferson Adams

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University. His articles, essays, poems, stories and book reviews have appeared in numerous magazines, journals, and websites, including North American Project, Antioch Review, Caliban, Mississippi Review, Slate, and more. He is the author of more than 2,500 articles on celiac disease. His university coursework includes studies in science, scientific methodology, biology, anatomy, physiology, medicine, logic, and advanced research. He previously devised health and medical content for Colgate, Dove, Pfizer, Sharecare, Walgreens, and more. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of numerous books, including "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

    >VIEW ALL ARTICLES BY JEFFERSON ADAMS

     


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-M):




  • Related Articles

    Jefferson Adams
    Will a new treatment enable people with celiac disease to ditch a gluten-free diet?
    About one in a hundred people in the United States is affected by celiac disease. If you're one of them, you know how hard it can be to maintain a strict gluten-free diet.
    Everyone's got their horror stories about trying to simply eat a meal, only to have a tiny amount of gluten wreck havoc on their digestive system.
    There are currently no therapeutics on the market to treat celiac disease, says Sydney Gordon, a scientist at Ab Initio Biotherapeutics. Sure, there are other over-the-counter enzyme treatments, Gordon adds, but most are slow to act, or don't break down enough gluten to prevent a reaction.
    "There are no other enzymes on the market for celiac disease," said Justin Siegel, the...


    Jefferson Adams
    Celiac.com 12/22/2017 - Venture capital firms Arch Venture, and Vatera are betting big on biotech startup ImmusanT, the makers of potential celiac disease vaccine Nexvax2.
    Arch and Vatera have funded a $40 million B round that will support ImmusanT's development of their celiac treatment through Phase II testing. Full data are expected in mid-2019.
    As part of it's efforts, Arch Venture partner and former head of research at Celgene, Tom Daniel, will join the board at ImmusanT. Additionally, renowned immunologist and Arch managing director Steven Gillis will also join the board at ImmusanT.
    Nexvax2 is the first prong in ImmusanT's efforts to develop a treatment that creates immune system tolerance to thwart autoimmune diseases. If they are successful in tackling celiac disease...


    Jefferson Adams
    Celiac.com 12/25/2017 - In the very near future, your personal microbiome may be the key to creating a customized treatment for celiac disease.
    That's because new advances in genome studies are promising to help create a customized, individual approach for treating numerous disorders, including celiac disease. Such individualized treatments may also help to reduce adverse events, and decrease health care costs.
    So far, a similar approach for optimizing preventive and therapeutic approaches in cancer using human genome sequencing has proven successful.
    Writing in the Mayo Clinic Proceedings, ad team of researches expounded on this approach. The research team included Purna C. Kashyap, Nicholas Chia, PhD, Heidi Nelson, MD, Eran Segal, PhD, and Eran Elinav, MD, PhD. They are variously...


  • Recent Activity

    1. - trents replied to SuzanneL's topic in Celiac Disease Pre-Diagnosis, Testing & Symptoms
      3

      Weak Positive Test

    2. - powerofpositivethinking posted a topic in Coping with Celiac Disease
      0

      Oh the Anomalies! This Forum Helped My Dog and Me

    3. - SuzanneL replied to SuzanneL's topic in Celiac Disease Pre-Diagnosis, Testing & Symptoms
      3

      Weak Positive Test

    4. - cristiana replied to Larzipan's topic in Related Issues & Disorders
      16

      Has anyone had terrible TMJ/ Jaw Pain from undiagnosed Celiac?

    5. - Julie Riordan replied to Julie Riordan's topic in Traveling with Celiac Disease
      3

      Any ideas for travelling


  • Celiac.com Sponsor (A19):



  • Member Statistics

    • Total Members
      120,506
    • Most Online (within 30 mins)
      7,748

    NanaA
    Newest Member
    NanaA
    Joined

  • Celiac.com Sponsor (A20):


  • Forum Statistics

    • Total Topics
      120.2k
    • Total Posts
      1m

  • Celiac.com Sponsor (A22):





  • Celiac.com Sponsor (A21):



  • Popular Now

    • JustGemi
    • Linedancegal
    • Hannah24
      9
    • jessiemariecar
    • Rhonda H
  • Popular Articles

    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
  • Upcoming Events

×
×
  • Create New...